MOUNTAIN VIEW, Calif., Sept. 8, 2011 /PRNewswire/ — Concentric
Medical, Inc., a global leader in acute ischemic stroke
intervention, today announced completion of enrollment of the TREVO
Study. The TREVO Study (Thrombectomy
REvascularization of large Vessel
Occlusions in acute ischemic stroke) is the first
evaluation of Stentriever™ technology in a European,
multicenter, prospective clinical trial. The TREVO Study was
designed to assess the ability of the Trevo® System to remove
the blood clots that cause strokes and to restore blood flow to the
The TREVO Study employed the latest generation of the Trevo®
Retrieval System and the preliminary results are very promising.
Interim data from the study were presented in May at the European
Stroke Congress by Professor Olav Jansen, Head of Neuroradiology at
Universitatsklinikum Schleswig-Holstein Kiel. The interim
revascularization rate in the first 36 patients was 96%. Thirty
patients had 90-day follow up and 63% of these had a good outcome.
A “good outcome” was defined as being functionally
independent at 90 days (modified Rankin score of 2 or less).
Professor Olav Jansen and Professor Nils Wahlgren, Professor of
Neurology at Karolinska University Hospital, are co-Principal
Investigators of the Study. Professor Wahlgren commented: “The
TREVO study represents an important step forward in the evidence
supporting the treatment of patients with moderate and severe
strokes with mechanical thrombectomy devices, such as the Trevo
System. The rigorous conduct of this prospective multicenter trial
provides more confidence not only in patient selection, but in the
successful procedural and clinical outcomes for these
“The Trevo System is the first device of this type designed
specifically for removal of the clot in ischemic stroke patients.
Not only was it easy to use, but the architectur